LETTER TO THE EDITOR

CrossMark

Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia

Vlatko Pejsa [1,2] (ORCID) · Marko Lucijanic [1] · Zeljko Jonjic [1] · Zeljko Prka [1] · Gorana Vukorepa [3]

Dear Editor,

Obinutuzumab is a humanized anti-CD20 monoclonal antibody that is currently recommended in combination with chlorambucil for first-line treatment of chronic lymphocytic leukemia (CLL) in patients unfit for fludarabine-based therapy. Although shown to be superior than rituximab in this setting [1], safety profile of obinutuzumab is not as well established. Progressive multifocal leukoencephalopathy (PML) is a severe, fatal, demyelinating disease of central nervous system (CNS) caused by reactivation of John Cunningham (JC) virus. Although very rare, it is associated with exposure to immunosuppressive agents like rituximab and other monoclonal antibodies. Only three PML cases have been reported in association with obinutuzumab exposure, but all of them were confounded with prior rituximab therapy [2]. Here, we report the first documented case of PML developing after exposure to obinutuzumab in a treatment-naïve patient treated for CLL.

A 62-year-old female patient was diagnosed with CLL in 2005. Her medical history included tuberculosis of left tibia in the childhood, pulmonary emphysema, and recurrent pneumonias, but no previous neurological disorders. Due to CLL progression and presence of comorbidities, she started obinutuzumab and chlorambucil in October 2017 and received a total of six cycles ending in April

2018, achieving complete remission. She had no chronic therapy for previous conditions and was concomitantly treated with allopurinol and ranitidine. In May 2018, she started complaining of progressively worsening blurred vision. Ophthalmologic examination did not identify the cause, but the CT and subsequent magnetic resonance T2-weighted images showed hyperintensive subcortical lesions (Fig. 1), initially indicative of posterior reversible encephalopathy syndrome (PRES). However, further radiologic progression of brain lesions, lack of clinical improvement, and confirmation of JC virus by polymerase chain reaction in the cerebrospinal fluid defined the diagnosis of PML. Despite radiologic progression of brain lesions, patient exhibited stable clinical course with only visual impairment for 5 months after first symptoms, but then rapid cognitive and neurologic deterioration occurred. A course of intravenous immunoglobulins was instituted, but without benefit. Patient remains alive, but seriously disabled, unable to care for herself with tendency for further deterioration at the time of this report, now 6 months after first occurrence of neurological symptoms.

PML is a serious demyelinating disease of CNS with no effective treatment available and almost always fatal outcome. Although a limited number of PML cases in association with obinutuzumab have been reported, all of these patients were exposed to prior rituximab therapy, thereby confounding the possible role of obinutuzumab as an incriminated agent. Our case clearly demonstrates that association between obinutuzumab and PML exists and undoubtedly confirms the safety precaution from the drug label. Obinutuzumab is more potent in terms of B cell depletion than rituximab [3] and it is expected to be increasingly used in the treatment of CLL and indolent B cell lymphomas. The current incidence of PML during obinutuzumab treatment is still unknown and further investigations regarding the incidence of PML associated with

✉ Vlatko Pejsa
vpejsa@kbd.hr

1 Department of Hematology, University Hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb, Croatia

2 School of Medicine, University of Zagreb, Zagreb, Croatia

3 Neurology Department, University Hospital Dubrava, Zagreb, Croatia

Fig. 1 Patient presented with bilateral occipital and right periinsular subcortical lesions. **a** Initial T2-weighted magnetic resonance (MR) brain image (June 2018) showing hyperintensive subcortical lesions bilaterally occipitally. **b** Progression of occipital lesions was observed on follow-up MR images (October 2018)

exposure to obinutuzumab are needed to clearly establish safety of such potent therapy. The question arises whether risk management strategies, such as used in the case of natalizumab [4], should be undertaken in obinutuzumab candidates as well.

Compliance with ethical standards

Conflict of interest VP, ML, and ZP have received a speaker honorarium from Roche. Other authors declare that they have no conflict of interest.

Ethical statement All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent Patient's family provided informed consent for publishing.

References

1. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. https://doi.org/10.1056/NEJMoa1313984
2. Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf 15(8):1003–1011. https://doi.org/10.1080/14740338.2016.1198775
3. Edelmann J, Gribben JG (2016) Obinutuzumab for the treatment of indolent lymphoma. Future Oncol 12(15):1769–1781. https://doi.org/10.2217/fon-2016-0084
4. Fernandez O (2013) Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord 6(2):69–79. https://doi.org/10.1177/1756285612470401